Press Release: BD Onclarity™ HPV Assay Receives FDA Approval for Use with Both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep^® Pap Test

The BD Onclarity™ HPV Assay has received FDA Approval for use with both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test, which expands access to the HPV test that more precisely identifies patients’ risk for cervical cancer.

“When more people with a cervix are better able to manage their health through more accurate and precise testing, we are taking another step forward toward eliminating cervical cancer in our lifetimes,” said Dr. Jeff Andrews, Vice President of Medical Affairs for BD.

ThinPrep is a trademark of Hologic, Inc.